SIENNANCT06541704
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 43 versions: 43 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Study sites: 231 to 233
- Minor Trial sites expanded: 225 → 231 locations
- Notable Eligibility criteria expanded, about 18 words
- Primary endpoints: details revised at 1 of 1 entry
- Study sites: 224 to 225
- Secondary endpoints: details revised at 1 of 15 entries
- Minor Site details revised at 1 of 224 sitesv40
- Study Status, Referencesv39
- Minor Study sites: 223 to 224v38
- Notable Primary completion pushed from Nov 29, 2027 to Jul 31, 2028
- Trial sites expanded: 218 → 223 locations
- Study completion pushed from May 21, 2032 to Apr 9, 2033
- Minor Study sites: 217 to 218v36
- Minor Study sites: 216 to 217v35
- Minor Site details revised at 2 of 216 sitesv34
- Minor Site details revised at 3 of 216 sitesv33
- Minor Trial sites expanded: 210 → 216 locationsv32
- Minor Study sites: 208 to 210v31
- Minor Study sites: 203 to 208v30
- Minor Study sites: 198 to 203v29
- Minor Study sites: 151 to 198v28
- Minor Study sites: 139 to 151v27
- Minor Study sites revised (139)v26
- Minor Study sites: 136 to 139v25
- Minor Study sites: 123 to 136v24
- Minor Study sites revised (123)v23
- Minor Study sites: 110 to 123v22
- Minor Study sites: 107 to 110v21
- Minor Study sites: 100 to 107v20
- Minor Study sites: 97 to 100v19
- Minor Study sites: 92 to 97v18
- Minor Study sites: 89 to 92v17
Notable Eligibility criteria expanded, about 14 wordsv16 Show 4 more changesShow less
- Primary endpoint revised
- Enrollment target: 750 to 975
- Study sites: 83 to 89
- Secondary endpoints revised (15)
- Minor Study sites: 78 to 83v15
- Minor Study sites: 71 to 78v14
- Minor Study sites: 68 to 71v13
- Minor Study sites: 66 to 68v12
- Minor Study sites: 46 to 66v11
- Minor Study sites: 45 to 46v10
- Minor Study sites: 44 to 45v9
- Minor Study sites: 41 to 44v8
- Minor Study sites: 30 to 41v7
- Minor Study sites: 27 to 30v6
- Minor Study sites: 19 to 27v5
- Minor Study sites: 13 to 19v4
- Minor Study sites: 8 to 13v3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Study sites: 0 to 8
- Primary completion date: Jul 10, 2027 to Nov 29, 2027
- Study completion date: Jan 5, 2032 to May 21, 2032
- Start date changed from estimate of Oct 28, 2024 to Oct 30, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline, measured by Fundus Autofluorescence (FAF)
Timeframe: To week 52
Secondary (15)
Loss of Best Corrected Visual Acuity (BCVA) ≥15 letters [Early Treatment Diabetic Retinopathy Study (ETDRS)] from baseline
Change from baseline in Low-Contrast quantitative Visual Acuity (LC-qVA)
Change from baseline in Low-Luminance Low-Contrast quantitative Visual Acuity (LL-LC-qVA)
Change from baseline in quantitative Contrast Sensitivity Function (qCSF)
Growth rate (slope) of total GA lesion area (mm^2 /year) from baseline measured by FAF
Show 10 moreShow less
Concentrations of total pozelimab in serum
Concentrations of total cemdisiran in plasma
Change from baseline in concentration of total Complement component 5 (C5)
Incidence of Antidrug antibody (ADA) to pozelimab
Magnitude of ADA to pozelimab
Incidence of ADA to cemdisiran
Magnitude of ADA to cemdisiran
Incidence of Neutralizing Antibody (NAb) to pozelimab
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Arms and interventions
Pozelimab + Cemdisiran treatment groupExperimental
Randomized 1:1:1
Cemdisiran monotherapy treatment groupExperimental
Randomized 1:1:1
Placebo treatment groupPlacebo comparator
Randomized 1:1:1
Drugs: Pozelimab, Cemdisiran, Placebo
Sites
233 sites in 11 countries
United States 160, Germany 16, France 13, Spain 11, Italy 9, United Kingdom 6, Australia 5, Hungary 5, Austria 3, Poland 3, Canada 2